“Immunotherapy for Cancer; Current status, toxicity awareness and management”

Bruce Brockstein, MD

Head, Division of Hematology/Oncology

Kellogg Scanlon Chair in Oncology, NorthShore University HealthSystem

Clinical Professor, University of Chicago Pritzker School of Medicine

Thomas Hensing, MD

Division of Oncology, NorthShore University HealthSytem

Clinical Associate Professor, University of Chicago Pritzker School of Medicine

Laura Schmidt, PharmD

Oncology Pharmacy, NorthShore University HealthSystem

Learning Objectives:

Bruce Brockstein, MD

1. List the spectrum of toxicities with checkpoint Inhibitor Immunotherapy
2. Develop comfort with the management of immunotherapy toxicities
3. Verbalize how development of toxicity negatively or positively affects outcomes

Thomas Hensing, MD

1. Articulate the mechanism of action for this novel class of cancer therapies
2. Improve capabilities for early diagnosis of immune related adverse events that are common with this class of agents

Laura Schmidt, PharmD

1. List the immune checkpoint inhibitors currently in use in oncology.
2. Discuss management strategies for immune checkpoint inhibitor related toxicity